fda restrictions bpc-157 compounding Legal Status: Regulations and Big win for $HIMS. The

Big win for $HIMS. The FDA advisory panel voted to allow compounding of BPC 157, KPV, TB 500 and MOTS C, opening the door to a multibillion dollar peptide market. Hims is positioned to capitalize. An FDA advisory committee voted Thursday to remove compounding restrictions on four peptides despite little evidence the products are safe or effective for medical use. In a series of 8 6 votes (with I just testified at an FDA meeting on whether seven popular peptides should be allowed in compounding. Just last month, FDA medical officers determined that none of the peptides met the agency's FDA advisory committee votes to add popular peptide BPC 157 to drug compounding list ABC News

SKU: 43185718057 · From webdevsolutions.tech